| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026743670 |
| P356 | DOI | 10.1186/1742-2094-11-74 |
| P932 | PMC publication ID | 4022085 |
| P698 | PubMed publication ID | 24722201 |
| P5875 | ResearchGate publication ID | 261603823 |
| P50 | author | Gerrit M. Grosse | Q86120943 |
| P2093 | author name string | Hans Worthmann | |
| Karin Weissenborn | |||
| Ralf Lichtinghagen | |||
| Henning Pflugrad | |||
| Meike Dirks | |||
| Ramona Schuppner | |||
| Anita B Tryc | |||
| P2860 | cites work | Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment | Q22306370 |
| The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion | Q24300435 | ||
| Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival | Q24676224 | ||
| CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. | Q24814510 | ||
| Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia | Q28140314 | ||
| A new class of membrane-bound chemokine with a CX3C motif | Q28303204 | ||
| Control of microglial neurotoxicity by the fractalkine receptor | Q28513748 | ||
| Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation | Q28564261 | ||
| Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia | Q28573077 | ||
| The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions | Q29615381 | ||
| Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke | Q29619330 | ||
| Monocytes: protagonists of infarct inflammation and repair after myocardial infarction | Q33942337 | ||
| CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. | Q34254575 | ||
| Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. | Q34391705 | ||
| CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. | Q34576624 | ||
| Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis | Q34828549 | ||
| Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques | Q35250952 | ||
| Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke. | Q36195292 | ||
| Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis | Q36660105 | ||
| Leukocyte infiltration in experimental stroke | Q37367461 | ||
| The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome | Q39871785 | ||
| Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial | Q39914319 | ||
| A role for spleen monocytes in post-ischemic brain inflammation and injury | Q41646625 | ||
| Monocyte subtypes predict clinical course and prognosis in human stroke | Q44698655 | ||
| CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents | Q45325019 | ||
| Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? | Q47895908 | ||
| Production and neuroprotective functions of fractalkine in the central nervous system | Q48258224 | ||
| Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. | Q48627196 | ||
| Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. | Q48715061 | ||
| Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. | Q49160789 | ||
| Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. | Q52549466 | ||
| Mild neurological symptoms despite middle cerebral artery occlusion. | Q53634128 | ||
| Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. | Q54573513 | ||
| Fractalkine is an independent predictor of mortality in patients with advanced heart failure | Q58071078 | ||
| The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia | Q73910771 | ||
| Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease | Q78594580 | ||
| P921 | main subject | temporal dynamics | Q124178693 |
| P304 | page(s) | 74 | |
| P577 | publication date | 2014-04-10 | |
| P1433 | published in | Journal of Neuroinflammation | Q15716679 |
| P1476 | title | The temporal dynamics of plasma fractalkine levels in ischemic stroke: association with clinical severity and outcome | |
| P478 | volume | 11 |
| Q104473891 | Distinct systemic cytokine networks in symptomatic and asymptomatic carotid stenosis |
| Q47805638 | Fractalkine in obstructive sleep apnea patients |
| Q38530348 | Fractalkine in the nervous system: neuroprotective or neurotoxic molecule? |
| Q38400503 | Modulation of platelet and monocyte function by the chemokine fractalkine (CX3 CL1) in cardiovascular disease |
| Q36846847 | Monocyte Subsets and Related Chemokines in Carotid Artery Stenosis and Ischemic Stroke |
| Q64256559 | Overexpression of CX3CR1 in Adipose-Derived Stem Cells Promotes Cell Migration and Functional Recovery After Experimental Intracerebral Hemorrhage |
Search more.